scholarly journals Therapeutic effects of mesenchymal stem cell transplantation on rat models of Parkinson's disease

2012 ◽  
Vol 124 (2) ◽  
pp. 111-114
Author(s):  
Feifei Wang ◽  
Takao Yasuhara ◽  
Masahiro Kameda ◽  
Isao Date
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Therapeutic Effects ◽  
Mesenchymal Stem Cell Transplantation ◽  
Rat Models

Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease

2010 ◽  
Vol 155 (2) ◽  
pp. 62-70 ◽  
Author(s):  
Neelam K. Venkataramana ◽  
Satish K.V. Kumar ◽  
Sudheer Balaraju ◽  
Radhika Chemmangattu Radhakrishnan ◽  
Abhilash Bansal ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Bone Marrow ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Mesenchymal Stem Cell Transplantation ◽  
Autologous Bone

Mesenchymal stem cell transplantation and aerobic exercise for Parkinson’s disease: therapeutic assets beyond the motor domain

2019 ◽  
Vol 30 (2) ◽  
pp. 165-178
Author(s):  
Jenny Berrío Sánchez ◽  
Jaison Cucarian Hurtado ◽  
Ramiro Barcos Nunes ◽  
Alcyr Alves de Oliveira
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Therapeutic Approaches ◽  
Mesenchymal Stem Cell Transplantation ◽  
Therapeutic Benefits

Abstract Parkinson’s disease (PD) is a very common neurodegenerative condition in which both motor and nonmotor deficits evolve throughout the course of the disease. Normally characterized as a movement disorder, PD has been broadly studied from a motor perspective. However, mild to moderate cognitive deficits began to appear in the early phases of the disease, even before motor disturbances actually manifest, and continue to progress relentlessly. These nonmotor manifestations are also a source of detriment to the patients’ already strained functionality and quality of life, and pose a therapeutic challenge seeing that replacing therapies have had conflicting results. Considering that the currently approved therapies can hardly be considered curative, efforts to find therapeutic approaches with an actual disease-modifying quality and capable of addressing not only motor but also cognitive dysfunctions are clearly needed. Among possible alternatives with such attribute, mesenchymal stem cell transplantation and exercise are worth highlighting given their common neuroprotective, neuroplastic, and immunomodulatory properties. In this paper, we will summarize the existent literature on the topic, focusing on the mechanisms of action through which these two approaches might beget therapeutic benefits for PD beyond the commonly assessed motor dysfunctions, alluding, at the same time, toward a potential synergic association of both therapies as an optimized approach for PD.

scholarly journals Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration

2020 ◽  
Author(s):  
Chun-Lei Deng ◽  
Cheng-Biao Hu ◽  
Sheng-Tao Ling ◽  
Na Zhao ◽  
Li-Hui Bao ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Retinal Degeneration ◽  
Cell Transplantation ◽  
Therapeutic Effects ◽  
Mesenchymal Stem Cell Transplantation ◽  
Programmed Cell Death 4 ◽  
Functional Regulation

Abstract Photoreceptor apoptosis is recognized as one key pathogenesis of retinal degeneration, the counteraction of which represents a promising approach to safeguard visual function. Recently, mesenchymal stem cell transplantation (MSCT) has demonstrated immense potential to treat ocular disorders, in which extracellular vesicles (EVs), particularly exosomes, have emerged as effective ophthalmological therapeutics. However, whether and how MSCT protects photoreceptors against apoptotic injuries remains largely unknown. Here, we discovered that intravitreal MSCT counteracted photoreceptor apoptosis and alleviated retinal morphological and functional degeneration in a mouse model of photoreceptor loss induced by N-methyl-N-nitrosourea (MNU). Interestingly, effects of MSCT were inhibited after blockade of exosomal generation by GW4869 preconditioning. Furthermore, MSC-derived exosomal transplantation (EXOT) effectively suppressed MNU-provoked photoreceptor injury. Notably, therapeutic efficacy of MSCT and EXOT on MNU-induced retinal degeneration was long-lasting as photoreceptor preservance and retinal maintenance were detected even after 1–2 months post to injection for only once. More importantly, using a natural occurring retinal degeneration model caused by a nonsense mutation of Phosphodiesterase 6b gene (Pde6bmut), we confirmed that MSCT and EXOT prevented photoreceptor loss and protected long-term retinal function. In deciphering therapeutic mechanisms regarding potential exosome-mediated communications, we identified that miR-21 critically maintained photoreceptor viability against MNU injury by targeting programmed cell death 4 (Pdcd4) and was transferred from MSC-derived exosomes in vivo for functional regulation. Moreover, miR-21 deficiency aggravated MNU-driven retinal injury and was restrained by EXOT. Further experiments revealed that miR-21 mediated therapeutic effects of EXOT on MNU-induced photoreceptor apoptosis and retinal dysfunction. These findings uncovered the efficacy and mechanism of MSCT-based photoreceptor protection, indicating exosomal miR-21 as a therapeutic for retinal degeneration.

Sign in / Sign up

Export Citation Format

Share Document